阿托伐他汀对脑梗死患者hs-CRP、MMP-9水平的影响

被引：26

作者：

王荔 ^{[1
]}

石娜 ^{[2
]}

张小菊 ^{[3
]}

王改青 ^{[1
]}

薛芳 ^{[1
]}

孙支唐 ^{[1
]}

机构：

[1] 山西医科大学第二医院

[2] 山西省中医院

[3] 山西省心血管病医院

来源：

卒中与神经疾病 | 2014年 / 21卷 / 01期

关键词：

阿托伐他汀; 炎症; 颈动脉粥样硬化; 脑梗死; hs-CRP; MMP-9;

D O I：

暂无

中图分类号：

R743.3 [急性脑血管疾病（中风）];

学科分类号：

1002 ;

摘要：

目的观察阿托伐他汀干预后脑梗死患者高敏C反应蛋白(hs-CRP)、基质金属蛋白酶-9(MMP-9)水平变化。方法选取急性动脉粥样硬化性血栓性脑梗死44例,分为两组,分别服用阿托伐他汀、阿司匹林组(A组)和单独服用阿司匹林组(NA组),测定3个月前后hs-CRP、MMP-9和血脂水平的变化。结果 A组hs-CRP,MMP-9水平均较治疗前显著下降(P<0.05),而NA组治疗前后无明显变化。治疗前后血脂水平比较A组TC、LDL-C水平显著下降,NA组变化不明显,TG在两组变化均不明显。结论阿托伐他汀可能通过减轻炎症反应来稳定颈动脉粥样硬化斑块,从而降低脑血管疾病的发生率和病死率。

引用

页码：23 / 25+66 +66

页数：4

共 20 条

[1] 强化阿托伐他汀对脑梗死患者C-反应蛋白的影响 [J].

郭晓燕 ;

李爱琼 ;

周捷 ;

詹冀 ;

梅元武 .

卒中与神经疾病, 2012, 19 (05) :294-296

[2]

他汀类药物预防缺血性卒中/短暂性脑缺血发作的专家建议[J]. 中华内科杂志. 2007(01)

[3]

The association of statin therapy and high-sensitivity C‐reactive protein level for predicting clinical outcome in acute non-cardioembolic ischemic stroke[J] . Nai-Wen Tsai,Lian-Hui Lee,Chi-Ren Huang,Wen-Neng Chang,Shang-Der Chen,Hung-Chen Wang,Yu-Jun Lin,Wei-Che Lin,Yi-Fang Chiang,Tsu-Kung Lin,Ben-Chung Cheng,Yu-Jih Su,Chia-Te Kung,Shu-Hua Hung,Hsueh-Wen Chang,Cheng-Hsien Lu.Clinica Chimica Acta . 2012 (23-2)

[4]

Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat[J] . Hiromi Kawai,Shoko Deguchi,Kentaro Deguchi,Toru Yamashita,Yasuyuki Ohta,Yoshio Omote,Tomoko Kurata,Yoshio Ikeda,Tohru Matsuura,Koji Abe.Brain Research . 2011

[5] Inflammatory biomarkers in coronary artery disease [J].

Zakynthinos, Epaminondas ;

Pappa, Nikolitsa .

JOURNAL OF CARDIOLOGY, 2009, 53 (03) :317-333

[6]

Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study[J] . G.F. Gensini,A.M. Gori,B. Dilaghi,C. Rostagno,A. Gaw,L.M. Blanco-Colio,E. de Teresa,J. Egido,C. Farsang,L.A. Leiter,P. Martineau,A. Nozza,A. Langer.International Journal of Cardiology . 2009 (3)

[7]

Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration[J] . Suguru Shiraya,Takashi Miyake,Motokuni Aoki,Fujiwara Yoshikazu,Shigetsugu Ohgi,Motonobu Nishimura,Toshio Ogihara,Ryuichi Morishita.Atherosclerosis . 2008 (1)

[8]

Effect of Intensive Atorvastatin Therapy on Prostaglandin E 2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndrome ? ? Conflicts of interest: Drs. Egido and Tu?ón have participated on advisory boards and have been invited speakers for Pfizer[J] . The American Journal of Cardiology . 2008 (1)

[9] Markers of instability in high-risk carotid plaques are reduced by statins [J].